Keywords pediatric renal cell carcinoma, TFE3, Xp11.2 translocation carcinomas, prognosis
|
|
- Gerard Clark
- 8 years ago
- Views:
Transcription
1 Xp11.2 Translocation Renal Cell Carcinomas Have a Poorer Prognosis Than Non-Xp11.2 Translocation Carcinomas in Children and Young Adults: A Meta-analysis International Journal of Surgical Pathology 18(6) The Author(s) 2010 Reprints and permission: sagepub.com/journalspermissions.nav DOI: / Qiu Rao, MD 1, Bing Guan, MD 1, and Xiao-jun Zhou, MD, PhD 1 Abstract Objectives. Renal cell carcinomas (RCCs) in children and adolescents are much rarer than in adults. In this age group, Xp11.2 translocation RCCs were the most common subtype of pediatric RCCs. Information regarding the clinical behavior of pediatric RCCs remains controversial because of their relatively rare incidence. The authors aimed to perform a systematic review and meta-analysis to better define the biological features of pediatric RCCs. Methods. Eligible studies were identified through multiple search strategies. Studies were assessed for quality using the Jadad Quality Scale. Data were collected comparing overall survival (OS), disease-free survival (DFS), and stage in patients with TFE3 + pediatric RCCs and TFE3 RCCs. Results. A total of 4 studies were included for meta-analysis, and pooled odds ratios (ORs) with 95% confidence interval (CI) were calculated. The meta-analysis outcomes showed that TFE3 + pediatric RCCs were significantly associated with poorer outcomes (OS and DFS) and a higher stage (III/IV) than TFE3 RCCs (pooled ORs for each group: 4.59 [95% CI = ] for OS; 5.79 [95% CI = ] for DFS; and 5.89 [95% CI = ] for stage). This result was also confirmed by OS and DFS curves (P =.005 and P =.001). Conclusions. Xp11.2 translocation carcinomas appear to have a poorer prognosis than non-xp11.2 translocation carcinomas in children and young adults. Keywords pediatric renal cell carcinoma, TFE3, Xp11.2 translocation carcinomas, prognosis Introduction Pediatric RCCs are relatively rare and account for only 2% to 6% of all renal neoplasms in children and young adults. 1 Recent data suggest that pediatric RCCs may be a different entity from adult RCCs, with distinct morphological features and genetic abnormalities, and Xp11.2 translocation carcinomas are the most common subtype of pediatric RCCs. 2-4 In the 2004 WHO renal tumor classification, Xp11.2 translocation carcinomas have been recognized as a distinctive pathological entity from adult RCCs. 5 These translocation RCCs are characterized by a number of different translocations involving the Xp11.2 chromosome, all of which result in gene fusions involving the TFE3 gene. 6 At least 5 distinct gene fusions involving TFE3 have been characterized in the literature. 2,7 TFE3 protein is thought to be constitutively overexpressed in Xp11.2 translocation carcinomas and can be specifically identified by immunohistochemistry. 8,9 A recently developed antibody of TFE3 protein has been shown to be a highly sensitive (97.5%) and specific (99.6%) marker in these tumors. 8 Although pediatric RCCs were recognized as a new entity from adult RCCs, information regarding the clinical behavior of pediatric RCCs remains controversial because of their relatively rare incidence, as can be seen when reviewing published data with prognostic reports. Some studies have suggested a good outcome for pediatric RCCs despite lymph node metastases. 10,11 However, some cases of translocation carcinomas were previously reported to have an aggressive clinical course. 12,13 To better define the biological features of pediatric RCCs and determine whether clinical outcome of TFE3 + pediatric RCCs differed from TFE3 RCCs in 1 Department of Pathology, Clinical School of Medical College of Nanjing University/Nanjing Jinling Hospital, Nanjing, Jiangsu , China Corresponding Author: Xiao-jun Zhou, Department of Pathology, Clinical School of Medical College of Nanjing University/Nanjing Jinling Hospital, Nanjing, Jiangsu , China zh_xjzhou81@yahoo.com.cn
2 Rao et al. 459 this age group, we performed a systematic review and meta-analysis. Materials and Methods Literature Search A computer-aided literature search of PubMed (MEDLINE), MEDLINE in-process and nonindexed citations, EMBASE, DARE, the Cochrane Library, Science Citation Index, and meeting abstracts was conducted. An initial search strategy using recognized search terms TFE3, prognosis, Xp11.2 translocation, and pediatric renal cell carcinomas was performed in July 2009 and then repeated in December Reference lists from identified primary studies were then searched to identify any studies missed by the electronic search strategies. Study Selection Abstracts of all candidate articles were read by 2 independent reviewers (QR and BG). Articles that could not be categorized based on title and abstract alone were retrieved for full-text review. These articles were independently read and checked for inclusion criteria. Disagreements were resolved through consensus with a third reviewer (XZ). Primary studies that reported data required for meta-analysis were identified and included. Authors of included studies were not contacted for additional, unreported data. Study Inclusion/Exclusion Criteria Inclusion criteria for primary studies were as follows: (1) All studies included TFE3 + pediatric RCCs and TFE3 pediatric RCCs with follow-up information; (2) all cases were submitted to immunostaining with TFE3 (SC-5958, Santa Cruz Biotechnology Inc, Santa Cruz, CA), and Xp11.2 translocation carcinomas were confirmed by TFE3 and/or molecular analysis. There was no language restriction for searching. Inclusion of otherwise eligible studies depended on the availability of translation resources for the language(s) concerned, but no such studies were identified. Reviews, nonoriginal articles, and case reports were excluded. All studies were carefully evaluated to identify duplicate patient populations. Criteria used to determine duplicate populations included study period, hospital, treatment information, and any additional inclusion criteria. Quality Assessment of Primary Studies Quality assessment was performed in each of the acceptable studies in duplicate by independent reviewers (QR and BG) using the Jadad Quality Scale. 14,15 Issues such as randomization, concealment of allocation, and blinding were assessed. Studies with a score 3 were considered to be of high quality. Data Extraction Data from all primary studies included were independently extracted by 2 reviewers (QR and BG). Data extraction fields for each study included the following: (1) demographic data regarding inclusion criteria, patient age, gender, and treatment during follow-up; (2) tumor data, including size, stage, grade, and metastases; (3) survival data, including overall survival (OS) and disease-free survival (DFS); and (4) other variables included number of patients lost and reasons for patients lost during follow-up. Our primary interest was to gather data on OS and DFS. We did, however, also perform analyses on stage because this was commonly reported in these studies. Data Analysis/Synthesis The studies included were divided into 3 groups for analysis: those with data regarding OS, those about DFS, and those regarding stage. Dichotomous data were expressed as odds ratios (ORs). Pooled ORs with 95% confidence intervals (CIs) were used in the Mantel-Haenszel fixed-effect model when no statistically significant heterogeneity was detected. A P of <.05 was chosen for significance. The heterogeneity of combined ORs was investigated using a χ 2 -based test of homogeneity and evaluation of the inconsistency index (I 2 ) statistic, which takes values from 0% to 100%. 16 We judged that heterogeneity was significant when the p value was less than 0.1. An I 2 value >50% was considered to represent substantial heterogeneity between studies. 17 In cases with substantial heterogeneity, random-effects models of DerSimonian-Laird were applied. Assessment of publication bias was performed for each of the pooled study groups using a funnel plot. All analyses were carried out using the statistical software Review Manager (Version 5.0 for Windows; the Cochrane Collaboration, Oxford, UK). We also estimated the OS and DFS curves between TFE3 + pediatric RCCs and TFE3 RCCs. Survival curves were constructed according to the method of Kaplan-Meier. Differences between the curves were assessed using the log rank test. A P of <.05 was considered statistically significant. Statistical analyses were performed using SPSS software, version 16.0 (SPSS, Chicago, IL). Results Description of Studies The abstracts and titles of 128 primary studies were identified for initial review using search strategies as described. Reviewers identified 118 potential studies for full-text
3 460 International Journal of Surgical Pathology 18(6) 118 studies identified using described search strategies 42 candidate studies 4 studies available for meta-analysis Figure 1. Flow chart of the meta-analysis Abbreviation: RCC, renal cell carcinoma. 76 excluded for case report and review 28 eliminated for inadequate data 10 excluded for only including TFE3 + pediatric RCCs review. On further review, 76 articles were eliminated because they were reviews or case reports; 28 were eliminated because there were inadequate data for meta-analysis, and 10 were excluded for only including TFE3 + pediatric RCCs (Figure 1). Given that several authors have multiple publications in this field, we took great care to ensure that data reported in each article were unique. Quality assessment using the Jadad Quality Scale, a composite scoring system with a maximum of 5 points, was performed on all 4 studies included for meta-analysis. 11,18-20 The following parameters were evaluated: randomized study, description of randomization, double-blinded study, description of double blinding, description of withdrawals, and dropouts. Studies with a total score greater than or equal to 3 were considered to be of high quality, whereas low-quality studies had scores less than or equal to 2. 14,21 The characteristics of retained studies are listed in Table 1. Publication bias is described as visual assessment of a funnel plot in Figure 2. There was no evidence for significant publication bias in each of the 3 pooled groups. Primary Outcomes In total, there were 83 patients in all 4 studies. The mean sample size for all studies was 20.8 patients (range, 11-46). The average age of all patients in 4 studies was 14.7 years (range, 2-25 years). Follow-up information and tumor stage were recorded for each of the included studies. Follow-up information was available for 76 cases, including 35 Xp11.2 translocation RCCs and 41 non-xp11.2 translocation carcinomas. Nephrectomy was performed at diagnosis in 70 patients; 12 patients underwent partial nephrectomy, and 1 patient underwent simple nephrectomy. The mean and median follow-up time was 60.9 and 50 months, respectively (range, months). Among the 35 patients with Xp11.2 translocation RCCs, 19 were alive with no evidence of disease, 14 died of disease, and 2 remained alive with disease. Of the 41 non-xp11.2 translocation carcinomas, 35 were alive and disease free at their most recent follow-up visits, 4 died of disease, and in 2 cases deaths were a result of other causes. Results of meta-analysis for OS and DFS showed that TFE3 + pediatric RCCs were significantly associated with a poorer OS and DFS than TFE3 RCCs with pooled ORs of 4.59 (95% CI = ) and 5.79 (95% CI = ), respectively (Figures 3A and 3B). There was no evidence for heterogeneity of the 4 available studies (I 2 statistic = 0%, P =.84; and I 2 statistic = 0%, P =.81). The pooled OR estimate for stage of the 4 studies was 5.89 (95% CI = ), with no evidence for significant heterogeneity between studies (I 2 statistic = 0%, P =.53). TFE3 + pediatric RCCs were significantly associated with a higher stage (III/IV) than TFE3 RCCs (Figure 3C). Survival Analyses Studying OS and DFS curves, we observed that TFE3 + pediatric RCCs were significantly more frequently associated with a poorer outcome than TFE3 RCCs (P =.005 and P =.001; Figure 4). Discussion RCCs in children and adolescents are much rarer than in adults. 22 In this age group, Xp11.2 translocation RCCs were the most common subtype of pediatric RCCs and have been recognized as a new entity in the 2004 WHO renal tumor classification. 1 The biological behavior of pediatric RCCs is controversial. Some studies have suggested a good prognosis for pediatric RCCs. 10,11 However, some cases of translocation carcinomas have been reported to have an aggressive clinical course. 12,13 In the study by Rais-Bahrami et al, 23 the authors suggested that Xp11.2 translocation RCCs have the potential for late recurrences. Geller et al 11 also reported that Xp11.2 translocation RCCs intended to present at advanced stage. When reviewing published articles with prognostic reports, there were few series of pediatric RCCs because of their relatively rare incidence, and a relevant systematic review with meta-analysis was lacking. In this study, we evaluated 4 primary studies from the published literature and compared OS, DFS, and stage in patients with TFE3 + pediatric RCCs and TFE3 RCCs. 11,18-20 Our metaanalysis outcomes showed that TFE3 + pediatric RCCs were significantly associated with poorer outcomes (OS and DFS) and a higher stage (III/IV) than TFE3 RCCs (pooled ORs for each group: 4.59 [95% CI = ] for OS; 5.79 [95% CI = ] for DFS; and 5.89 [95% CI = ] for stage). This result was also confirmed by OS and DFS curves (P =.005 and P =.001). Although we did not observe significant heterogeneity or publication bias between studies, it is important to note
4 Rao et al. 461 Table 1. Characteristics of Included Studies References Study Design Number of Patients (M/F) Number of Patients TFE3+/ TFE3 TFE3 Detection Method Geller et al 11 C, R 11 (3/8) 7/4 Antibody Ramphal et al 16 C, R 13 (5/8) 7/6 Antibody Rao et al 18 C, R 46 (17/19) 19/27 Antibody Wu et al 17 C, R 13 (9/4) 6/7 Antibody Treatment RN PN SN Tumor Stage I/II (III/IV) Odds Ratios Jadad Score (7) Estimated (5) Estimated (24) Estimated (4) Estimated 3 Abbreviations: C, consecutive; R, retrospective; RN, radical nephrectomy; PN, partial nephrectomy; SN, simple nephrectomy. Figure 2. Bias assessment plots for studies included in all 3 meta-analyses: there was no evidence for significant publication bias in any of the 3 pooled groups. Plots are arranged as follows: A. Overall survival. B. Disease-free survival. C. Stage evaluation Abbreviation: SE, standard error; OR, odds ratio; RCC, renal cell carcinoma.
5 462 International Journal of Surgical Pathology 18(6) Figure 3. Forrest plots and meta-analysis of studies evaluating odds ratios of TFE + pediatric RCCs as compared with TFE RCCs: survival and stage data are reported as follows: A. Overall survival. B. Disease-free survival. C. Stage evaluation Abbreviation: RCC, renal cell carcinoma; CI, confidence interval. Figure 4. Overall survival (A) and disease-free survival (B) analyses were computed comparing TFE + pediatric RCCs with TFE RCCs. TFE + pediatric RCCs were significantly more frequently associated with a poorer outcome than TFE RCCs (Kaplan-Meier analysis; P =.005 and P =.001) Abbreviation: RCC, renal cell carcinoma.
6 Rao et al. 463 that because of the small number and sample size of primary studies analyzed in each group, not extending our search criteria to other sources of unpublished data, with a number of patients in 1 study without follow-up, possibly leading to an attrition bias, could have potentially limited the power to detect important differences. The presented ORs might, therefore, be an overestimation of the true effect size. In conclusion, this meta-analysis of the current bestavailable evidence demonstrated that TFE3 + pediatric RCCs were significantly associated with a poorer outcomes (OS and DFS) and a higher stage (III/IV) than TFE3 RCCs. The results provide strong grounds for stating that any RCC in children and young adults should be subjected to immunostaining with TFE3, a highly sensitive (97.5%) and specific (99.6%) marker, 8 to identify these translocation carcinomas, and patients with TFE3 + pediatric RCCs could benefit from a stricter follow-up. We also recognize that this evidence must be interpreted with some caution because of the relatively poor quality of study design. Therefore, further investigations on larger and more heterogeneous studies should be carried out to validate and extend our results. Acknowledgment We are indebted to the authors of the primary studies included in this meta-analysis. Declaration of Conflicting Interests The author(s) declared no potential conflicts of interest with respect to the authorship and/or publication of this article. Funding The author(s) received no financial support for the research and/ or authorship of this article. References 1. Cook A, Lorenzo AJ, Salle JL, et al. Pediatric renal cell carcinoma: single institution 25-year case series and initial experience with partial nephrectomy. J Urol. 2006;175: ; discussion Argani P. The evolving story of renal translocation carcinomas. Am J Clin Pathol. 2006;126: Winarti NW, Argani P, De Marzo AM, et al. Pediatric renal cell carcinoma associated with Xp11.2 translocation/tfe3 gene fusion. Int J Surg Pathol. 2008;16: Jing H, Tai Y, Xu D, et al. Renal cell carcinoma associated with Xp11.2 translocations, report of a case [published online ahead of print October 23, 2009]. Urology. doi: / j.urology Lopez-Beltran A, Scarpelli M, Montironi R, et al WHO classification of the renal tumors of the adults. Eur Urol. 2006;49: Martignoni G, Pea M, Gobbo S, et al. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Mod Pathol. 2009; 22: Argani P, Ladanyi M. Recent advances in pediatric renal neoplasia. Adv Anat Pathol. 2003;10: Argani P, Lal P, Hutchinson B, et al. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003;27: Dickson BC, Brooks JS, Pasha TL, et al. TFE3 expression in tumors of the microphthalmia-associated transcription factor (MiTF) family [published online ahead of print February 16, 2010]. Int J Surg Pathol. doi: v Geller JI, Dome JS. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer. 2004;101: Geller JI, Argani P, Adeniran A, et al. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer. 2008;112: Bovio IM, Allan R, Oliai B, et al. Xp11.2 translocation renal carcinoma with placental metastasis: a case report [published online ahead of print January 22, 2009]. Int J Surg Pathol. doi: v Koie T, Yoneyama T, Hashimoto Y, et al. An aggressive course of Xp11 translocation renal cell carcinoma in a 28-year-old man. Int J Urol. 2009;16: Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17: Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med. 2001;135: Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21: Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327: Ramphal R, Pappo A, Zielenska M, et al. Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the mit transcription factor family. Am J Clin Pathol. 2006;126: Wu A, Kunju LP, Cheng L, et al. Renal cell carcinoma in children and young adults: analysis of clinicopathological, immunohistochemical and molecular characteristics with an emphasis on the spectrum of Xp11.2 translocation-associated and unusual clear cell subtypes. Histopathology. 2008;53: Rao Q, Chen YJ, Wang DJ, et al. Renal cell carcinoma in children and young adults: clinicopathological, immunohistochemical, and VHL gene analysis of 46 cases with follow-up [published online ahead of print December 24, 2009]. Int J Surg Pathol. doi: v1.
7 464 International Journal of Surgical Pathology 18(6) 21. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352: Srigley JR, Delahunt B. Uncommon and recently described renal carcinomas. Mod Pathol. 2009;22(suppl 2):S2-S Rais-Bahrami S, Drabick JJ, De Marzo AM, et al. Xp11 translocation renal cell carcinoma: delayed but massive and lethal metastases of a chemotherapyassociated secondary malignancy. Urology. 2007;70:178. e3-e6.
Classificazione anatomo-patologica nei RCC Matteo Brunelli. Department of Pathology and Diagnostic, University di Verona, Italy
Classificazione anatomo-patologica nei RCC Matteo Brunelli Department of Pathology and Diagnostic, University di Verona, Italy WHO 2004 AFIP 2004 = ISUP Vancouver Classification 2013 5 newentities 3 emerging
More informationKIDNEY CARCINOMA ASSOCIATED WITH XP11.2 TRANSLOCATION / TFE3 (ASPL-TFE3) GENE FUSION
Case Report International Braz J Urol Official Journal of the Brazilian Society of Urology KIDNEY CA AND Xp11.2 TRANSLOCATION Vol. 31 (3): 251-255, May - June, 2005 KIDNEY CARCINOMA ASSOCIATED WITH XP11.2
More informationIf several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.
General Remarks This template of a data extraction form is intended to help you to start developing your own data extraction form, it certainly has to be adapted to your specific question. Delete unnecessary
More informationSomething Old, Something New.
Something Old, Something New. Michelle A. Fajardo, D.O. Loma Linda University Medical Center Clinical Presentation 6 year old boy, presented with hematuria Renal mass demonstrated by ultrasound & CT scan
More informationTumori rari del rene: trattamento per stadio ed istologia Dr. Camillo Porta
Tumori rari del rene: trattamento per stadio ed istologia Dr. Camillo Porta S.C. di Oncologia Medica, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia Non-Clear Cell Renal Cell Carcinoma (nccrcc) nccrcc
More informationSeattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.
Seattle Montreal IAP September 2006 Case Presentations Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Clinical Professor of Pathology University of British Columbia Case
More informationRenal Pathology Update. Sundus Hussein MD, FRCPC
Renal Pathology Update Sundus Hussein MD, FRCPC Case History A 45 year old male with incidentally discovered a 3.5 x 3.9 x 2.7 cm renal mass Handling partial nephrectomy Handling partial nephrectomy
More informationRENAL CANCER PATHOLOGY WHAT REALLY MATTERS? STEWART FLEMING UNIVERSITY OF DUNDEE
RENAL CANCER PATHOLOGY WHAT REALLY MATTERS? STEWART FLEMING UNIVERSITY OF DUNDEE MAJOR PARADIGM SHIFT IN EARLY 1990S IN UNDERSTANDING RENAL CANCER Molecular differential pathology of renal cell tumours
More informationPreliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors
Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors John Goldberg 1 *, George Demetri 2, Edwin Choy 3, Lee Rosen 4, Alberto
More informationNew Concepts and Refinements to. Existing WHO (2004) Renal Cell. Tumor Categories In Adults
New Concepts and Refinements to Existing WHO (2004) Renal Cell Tumor Categories In Adults Dr Varsha Manucha Assistant Professor Department of Pathology and Laboratory Medicine Temple University Hospital
More informationCT and MRI features of the Pathologic Subtypes of Papillary Renal Cell Carcinoma. Melissa Price, MD Aoife Kilcoyne, MD Mukesh G.
CT and MRI features of the Pathologic Subtypes of Papillary Renal Cell Carcinoma Melissa Price, MD Aoife Kilcoyne, MD Mukesh G. Harisinghani, MD Disclosures Neither I nor my immediate family members have
More informationTranslocation Renal Cell Carcinomas
Translocation Renal Cell Carcinomas Cora N. Sternberg, MD, FACP Chair, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Kidney cancer is not a single disease Clear cell (75%)
More informationPCORI Methodology Standards: Academic Curriculum. 2016 Patient-Centered Outcomes Research Institute. All Rights Reserved.
PCORI Methodology Standards: Academic Curriculum 2016 Patient-Centered Outcomes Research Institute. All Rights Reserved. Module 5: Step 3 Search the Literature Category 11: Systematic Reviews Prepared
More informationRenal Tumors with Eosinophilic Cytoplasm: 2013 Classification. Jesse K. McKenney, MD Associate Head, Surgical Pathology
Renal Tumors with Eosinophilic Cytoplasm: 2013 Classification Jesse K. McKenney, MD Associate Head, Surgical Pathology Renal Epithelial Neoplasia History 1981: WHO Classification of Renal Neoplasms 1.
More informationUnderstanding, appraising and reporting meta-analyses that use individual participant data
Understanding, appraising and reporting meta-analyses that use individual participant data Jayne Tierney, Claire Vale, Maroeska Rovers, Lesley Stewart IPD Meta-analysis Methods Group 21 st Annual Cochrane
More informationRenal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD
Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD Department of Pathology University of Szeged, Hungary ISUP Vancouver Classification of Renal Neoplasia Am J Surg Pathol 37:14691489, 2013 13 histologic
More informationMolecular heterogeneity of TFE3 activation in renal cell carcinomas
308 & 2012 USCAP, Inc. All rights reserved 0893-3952/12 $32.00 Molecular heterogeneity of TFE3 activation in renal cell carcinomas Stephan Macher-Goeppinger 1,2, Wilfried Roth 1,2, Nina Wagener 3, Markus
More informationSystematic Reviews and Meta-analyses
Systematic Reviews and Meta-analyses Introduction A systematic review (also called an overview) attempts to summarize the scientific evidence related to treatment, causation, diagnosis, or prognosis of
More informationNEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationTranslocation Renal Cell Carcinomas: Molecular insights and Future Directions
Translocation Renal Cell Carcinomas: Molecular insights and Future Directions Gabriel G. Malouf, MD, PhD Assistant professor Department of medical oncology Pitié-Salpêtrière Hospital, Paris, France Background
More informationUpdate on Mesothelioma
November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical
More informationStage IV Renal Cell Carcinoma. Changing Management in A Comprehensive Community Cancer Center. Susquehanna Health Cancer Center
Stage IV Renal Cell Carcinoma Changing Management in A Comprehensive Community Cancer Center Susquehanna Health Cancer Center 2000 2009 Warren L. Robinson, MD, FACP January 27, 2014 Introduction 65,150
More informationXP11.2 Translocation renal cell carcinoma: Clinical experience of Taipei Veterans General Hospital
Available online at www.sciencedirect.com Journal of the Chinese Medical Association 74 (2011) 500e504 Original Article XP11.2 Translocation renal cell carcinoma: Clinical experience of Taipei Veterans
More informationRENAL CELL CARCINOMA EPIDEMIOLOGY
RENAL CELL CARCINOMA: THE 2012 ISUP VANCOUVER CLASSIFICATION David Grignon MD, Indiana University, Indianapolis, IN RENAL CELL CARCINOMA EPIDEMIOLOGY Siegel et al. CaA Cancer J Clin 63:11-30, 2013 1 EPITHELIAL
More informationSuccesses and Limitations of Targeted Therapies in Renal Cell Carcinoma
g Tumor Res. Basel, Karger, 2014, vol 41, pp 98 112 (DOI: 10.1159/000355906) Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma Marc Pracht Dominik Berthold Medical Oncology Unit,
More informationJOURNAL OF CLINICAL ONCOLOGY DIAGNOSIS IN ONCOLOGY
VOLUME 28 NUMER 34 DECEMER 1 2010 JOURNL OF CLINICL ONCOLOGY DIGNOSIS IN ONCOLOGY Renal Cell Carcinoma With t(6;11) Translocation: Patient Case With a Novel lpha- Fusion Point Renal cell carcinoma (RCC)
More informationWeb appendix: Supplementary material. Appendix 1 (on-line): Medline search strategy
Web appendix: Supplementary material Appendix 1 (on-line): Medline search strategy exp Venous Thrombosis/ Deep vein thrombosis.mp. Pulmonary embolism.mp. or exp Pulmonary Embolism/ recurrent venous thromboembolism.mp.
More informationTreatment of seizures in multiple sclerosis (Review)
Koch MW, Polman SKL, Uyttenboogaart M, De Keyser J This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 009, Issue 3 http://www.thecochranelibrary.com
More informationThe Whipple Operation for Pancreatic Cancer: Optimism vs. Reality. Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006
The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006 Overview Pancreatic ductal adenocarcinoma Pancreaticoduodenectomy
More informationOutline. Publication and other reporting biases; funnel plots and asymmetry tests. The dissemination of evidence...
Cochrane Methodology Annual Training Assessing Risk Of Bias In Cochrane Systematic Reviews Loughborough UK, March 0 Publication and other reporting biases; funnel plots and asymmetry tests Outline Sources
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationEffects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationPrinciples of Systematic Review: Focus on Alcoholism Treatment
Principles of Systematic Review: Focus on Alcoholism Treatment Manit Srisurapanont, M.D. Professor of Psychiatry Department of Psychiatry, Faculty of Medicine, Chiang Mai University For Symposium 1A: Systematic
More informationHistologic Subtypes of Renal Cell Carcinoma
Histologic Subtypes of Renal Cell Carcinoma M. Scott Lucia, MD Associate Professor Chief of Genitourinary and Renal Pathology Director, Prostate Diagnostic Laboratory Dept. of Pathology University of Colorado
More informationCan I have FAITH in this Review?
Can I have FAITH in this Review? Find Appraise Include Total Heterogeneity Paul Glasziou Centre for Research in Evidence Based Practice Bond University What do you do? For an acutely ill patient, you do
More informationOncological outcome of surgical treatment in 336 patients with renal cell carcinoma
窑 Original Article 窑 Chinese Journal of Cancer Oncological outcome of surgical treatment in 336 patients with renal cell carcinoma Zhi Ling Zhang,2, Yong Hong Li,2, Yong Hong Xiong 3, Guo Liang Hou,2,
More informationDoes Selenium protect against lung cancer? Do Selenium supplements reduce the incidence of lung cancer in healthy individuals?
Does Selenium protect against lung cancer? Do Selenium supplements reduce the incidence of lung cancer in healthy individuals? Alexander Blakes and Eleanor Brunt October 2014 The question Mr Wilson s father
More informationUpdate on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward
Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward 33 rd Annual Internal Medicine Update December 5, 2015 Ryan C. Hedgepeth, MD, MS Chief of
More informationEffective Health Care Program
Comparative Effectiveness Review Number 152 Effective Health Care Program Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer Executive Summary Background Nature and Burden of Nonmetastatic Muscle-Invasive
More informationIntroduction. Wu A, Kunju L P, Cheng L & Shah R B (2008) Histopathology 53, 533 544
Histopathology 2008, 53, 533 544. DOI: 10.1111/j.1365-2559.2008.03151.x Renal cell carcinoma in children and young adults: analysis of clinicopathological, immunohistochemical and molecular characteristics
More informationThe role of Immunohistochemistry in diagnosis of renal cell carcinoma subtypes.
Asian Archives of Pathology 2013; Vol. 9 No.1, 9-16 Original articles The role of Immunohistochemistry in diagnosis of renal cell carcinoma subtypes. Sutthiporn Namnak, BSc *, Wipawee Kittikowit, MD *,
More informationBreast cancer treatment for elderly women: a systematic review
Breast cancer treatment for elderly women: a systematic review Gerlinde Pilkington Rumona Dickson Anna Sanniti Funded by the NCEI and POI Elderly people less likely to receive chemotherapy than younger
More informationEvidence-based Practice Center Comparative Effectiveness Review Protocol
Evidence-based Practice Center Comparative Effectiveness Review Protocol Project Title: Comparative Effectiveness of Case Management for Adults With Medical Illness and Complex Care Needs I. Background
More informationRenal Cell Carcinoma Associated with Xp11.2 Translocation: Clinicopathologic and Immunohistochemical Findings of 4 Cases
The Korean Journal of Pathology 2005; 39: 406-11 Renal Cell Carcinoma Associated with Xp11.2 Translocation: Clinicopathologic and Immunohistochemical Findings of 4 Cases Sanghui Park Ji-Eun Kwon Yeon-Lim
More informationHow To Write A Systematic Review
Formulating the Review Question & Writing a Protocol Madhukar Pai, MD, PhD Associate Professor Department of Epidemiology & Biostatistics McGill University, Montreal, Canada Email: madhukar.pai@mcgill.ca
More informationValidation and utilization of a TFE3 breakapart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma
Pradhan et al. Diagnostic Pathology (2015) 10:179 DOI 10.1186/s13000-015-0412-z RESEARCH Open Access Validation and utilization of a TFE3 breakapart FISH assay for Xp11.2 translocation renal cell carcinoma
More informationEffectiveness of Clinical Pathway in Breast Cancer Patients: A Meta-Analysis
Global Journal of Oncologist, 2014, 2, 15-21 15 Effectiveness of Clinical Pathway in Breast Cancer Patients: A Meta-Analysis Qi Cui 1,2, Jinhui Tian 2, Xuping Song 2, Kehu Yang 2 and Peizhen Zhang *,3
More informationForm B-1. Inclusion form for the effectiveness of different methods of toilet training for bowel and bladder control
Form B-1. Inclusion form for the effectiveness of different methods of toilet training for bowel and bladder control Form B-2. Assessment of methodology for non-randomized controlled trials for the effectiveness
More informationKIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA
KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,
More informationChanges in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
More informationCarcinoma papilar renal, cromófobo y otras histologías. Maria José Méndez Vidal Servicio de oncología Medica Hospital Reina Sofía Córdoba
Carcinoma papilar renal, cromófobo y otras histologías. Maria José Méndez Vidal Servicio de oncología Medica Hospital Reina Sofía Córdoba Europe 121 629 new cases RCC 2012, 75 676 affected men Slide 3
More information2. Background This was the fourth submission for everolimus requesting listing for clear cell renal carcinoma.
PUBLIC SUMMARY DOCUMENT Product: Everolimus, tablets, 5 mg and 10 mg, Afinitor Sponsor: Novartis Pharmaceuticals Australia Pty Ltd Date of PBAC Consideration: November 2011 1. Purpose of Application To
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationMeasures of Prognosis. Sukon Kanchanaraksa, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationTreatment and Surveillance of Non- Muscle Invasive Bladder Cancer
Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer David Josephson, MD FACS Fellowship Director, Urologic Oncology and Robotic Surgery Program Staging Most important in risk assessment and
More informationHow To Use A Breast Cancer Test To Help You Choose Chemotherapy
Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat Issued: September
More informationSaturation Biopsy for Diagnosis and Staging of Prostate Cancer. Original Policy Date
MP 7.01.101 Saturation Biopsy for Diagnosis and Staging of Prostate Cancer Medical Policy Section Surgery Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date /12/2013 Return to Medical Policy
More informationMAJOR PARADIGM SHIFT IN EARLY 1990S IN UNDERSTANDING RENAL CANCER
Renal tumours WHO 4 MAJOR PARADIGM SHIFT IN EARLY 1990S IN UNDERSTANDING RENAL CANCER Molecular differential pathology of renal cell tumours G. KOVACS A CLASSIFICATION BASED ON UNDERSTANDING THE GENETIC
More informationHER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
More informationProstate Cancer Screening in Taiwan: a must
Prostate Cancer Screening in Taiwan: a must 吳 俊 德 基 隆 長 庚 醫 院 台 灣 醫 學 會 105 th What is the PSA test? The blood level of PSA is often elevated in men with prostate cancer, and the PSA test was originally
More informationPrepared by:jane Healey (Email: janie_healey@yahoo.com) 4 th year undergraduate occupational therapy student, University of Western Sydney
1 There is fair (2b) level evidence that living skills training is effective at improving independence in food preparation, money management, personal possessions, and efficacy, in adults with persistent
More informationRole of histopatological assessment of renal cancer specimen after radical and partial nephrectomy
Role of histopatological assessment of renal cancer specimen after radical and partial nephrectomy Dr hab. n. med. Agnieszka Korolczuk Joanna Irla Natalia Pieszek Monika Orzeł Dr hab. n. med. Justyna Szumiło
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationCollected systematic reviews for the topic: Interventions to prevent occupational injuries in teen workers
The PEROSH OSH Evidence Search Documentation Form Collected systematic reviews for the topic: Interventions to prevent occupational injuries in teen workers No. Reference Study grading (sum of R-AMSTAR
More informationMetastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
More informationMethods for Meta-analysis in Medical Research
Methods for Meta-analysis in Medical Research Alex J. Sutton University of Leicester, UK Keith R. Abrams University of Leicester, UK David R. Jones University of Leicester, UK Trevor A. Sheldon University
More informationEpithelial Tumors of the Kidney Diagnostic Problems and Recently Described Entities
Pathology of Renal Neoplasia Epithelial Tumors of the Kidney Diagnostic Problems and Recently Described Entities Wael A Sakr, MD Wayne State University School of Medicine CURRENT CLASSIFICATION = EPITHELIAL
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Impact of uncertainty on cost-effectiveness analysis of medical strategies: the case of highdose chemotherapy for breast cancer patients Marino P, Siani C, Roche H, Moatti J P Record Status This is a critical
More informationLEVEL ONE MODULE EXAM PART ONE [Clinical Questions Literature Searching Types of Research Levels of Evidence Appraisal Scales Statistic Terminology]
1. What does the letter I correspond to in the PICO format? A. Interdisciplinary B. Interference C. Intersession D. Intervention 2. Which step of the evidence-based practice process incorporates clinical
More informationPSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.
PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition weiss@umdnj.edu September 23, 2010 Screening: 3 tests for PCa A good screening
More informationThe evolving pathology of solitary fibrous tumours. Luciane Dreher Irion MREH / CMFT / NSOPS
The evolving pathology of solitary fibrous tumours Luciane Dreher Irion MREH / CMFT / NSOPS Historical review Haemangiopericytoma (HPC) first described primarily as a soft tissue vascular tumour of pericytic
More informationGUIDELINES ADJUVANT SYSTEMIC BREAST CANCER
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
More informationA 70-year old Man with Pleural Effusion
Mesothelioma Diagnosis: Pitfalls and Latest Updates S Klebe and DW Henderson Recommendations Indisputable malignant cells on cytomorphological criteria which demonstrate a mesothelial phenotype, which
More informationA New Biomarker in Prostate Cancer Care: Oncotype Dx. David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY
A New Biomarker in Prostate Cancer Care: Oncotype Dx David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY Learning Objectives Review the current challenges in the prediction and prognosis of
More informationEnsemble Learning of Colorectal Cancer Survival Rates
Ensemble Learning of Colorectal Cancer Survival Rates Chris Roadknight School of Computing Science University of Nottingham Malaysia Campus Malaysia Chris.roadknight@nottingham.edu.my Uwe Aickelin School
More informationTitle Older people s participation and engagement in falls prevention interventions: Comparing rates and settings
Title Older people s participation and engagement in falls prevention interventions: Comparing rates and settings Keywords: patient adherence; falls, accidental; intervention studies; patient participation;
More informationIndependent Validation of the Prognostic Gene Expression Ratio Test in Formalin Fixed, Paraffin Embedded (FFPE) Mesothelioma Tumor Tissue Specimens
Independent Validation of the Prognostic Gene Expression Ratio Test in Formalin Fixed, Paraffin Embedded (FFPE) Mesothelioma Tumor Tissue Specimens Assunta De Rienzo, Ph.D. 1, Robert W. Cook, Ph.D. 2,
More informationThe 4Kscore blood test for risk of aggressive prostate cancer
The 4Kscore blood test for risk of aggressive prostate cancer Prostate cancer tests When to use the 4Kscore Test? Screening Prior to 1 st biopsy Prior to negative previous biopsy Prognosis in Gleason 6
More informationMedullary Renal Cell Carcinoma Case Report
Bahrain Medical Bulletin, Vol. 27, No. 4, December 2005 Medullary Renal Cell Carcinoma Case Report Mohammed Abdulla Al-Tantawi MBBCH, CABS* Abdul Amir Issa MBBCH, CABS*** Mohammed Abdulla MBBCH, CABS**
More informationProstatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.
Adjuvante und Salvage Radiotherapie Ludwig Plasswilm Klinik für Radio-Onkologie, KSSG CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS 1983 1998 Clinical stage T1 and T2 Mean
More informationRecent Advances in Renal Cell Carcinoma Associated with Xp11.2 Translocations/TFE Gene Fusions
North American Journal of Medicine and Science Jan 2012 Vol 5 No.1 43 Review Recent Advances in Renal Cell Carcinoma Associated with Xp11.2 Translocations/TFE Gene Fusions Yunguang Liu, MD, PhD; 1 Bo Xu,
More informationBeyond the PSA: Genomic Testing in Localized Prostate Cancer
Beyond the PSA: Genomic Testing in Localized Prostate Cancer Kelvin A. Moses, MD, PhD Vanderbilt University Medical Center Wednesday, December 2, 2015 5:00 p.m. ET/2:00 p.m. PT About ZERO ZERO s mission
More informationIntegrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
More informationMunich Cancer Registry
Munich Cancer Registry Baseline statistics Selection Matrix Homepage Deutsch Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany http://www.tumorregister-muenchen.de/en
More informationEffects of clinical pathways in stroke management: A meta-analysis
Neurology Asia 2015; 20(4) : 335 342 Effects of clinical pathways in stroke management: A meta-analysis 1,2,3 Di Huang, 1,2,3 XuPing Song, 2,3 Jinhui Tian, 1,2,3 Qi Cui, 1,2,3 Kehu Yang 1 School of Public
More informationImpact of radiation therapy on survival in patients with triple negative breast cancer
548 Impact of radiation therapy on survival in patients with triple negative breast cancer LAUREN T. STEWARD 1, FENG GAO 2, MARIE A. TAYLOR 3 and JULIE A. MARGENTHALER 1 1 Department of Surgery; 2 Division
More informationIssues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC)
Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC) FDA Presentation ODAC Meeting September 14, 2011 1 Review Team Paul G. Kluetz,
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in
More informationPredominance of ERG negative high grade prostate cancers in African American men
982 Predominance of ERG negative high grade prostate cancers in African American men JAMES FARRELL 1,2, DENISE YOUNG 1, YONGMEI CHEN 1, JENNIFER CULLEN 1, INGER L. ROSNER 1,2, JACOB KAGAN 3, SUDHIR SRIVASTAVA
More informationSUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:
More informationPediatric renal cell carcinoma
Journal of Pediatric Urology (2009) 5, 308e314 EDUCATIONAL ARTICLE Pediatric renal cell carcinoma Justin E. Sausville a, *, David J. Hernandez a, Pedram Argani b, John P. Gearhart a a James Buchanan Brady
More informationMalignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
More informationAnalysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data
The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500
More information8 General discussion. Chapter 8: general discussion 95
8 General discussion The major pathologic events characterizing temporomandibular joint osteoarthritis include synovitis and internal derangements, giving rise to pain and restricted mobility of the temporomandibular
More informationGleason Score. Oncotype DX GPS. identified for. about surveillance. time to get sophisticated
patient: MARK SMITH PSA 6.2 Gleason Score 6 Oncotype DX GPS 8 identified for active surveillance time to get sophisticated about surveillance Accurate prediction of prostate cancer risk is needed at the
More information